Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis

Respiratory Research

Volumn 13, Issue , 2012, Pages

  Chang, William Y C ^a   Cane, Jennifer L ^a   Blakey, John D ^a   Kumaran, Maruti ^b   Pointon, Kate S ^b   Johnson, Simon R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Angiotensin converting enzyme; ERS LAM guidelines; Matrix metalloproteinase; VEGF D

Indexed keywords

BIOLOGICAL MARKER; BRONCHODILATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; GELATINASE A; GELATINASE B; PROGESTERONE; VASCULOTROPIN D; MMP2 PROTEIN, HUMAN;

ADULT; ANGIOMYOLIPOMA; ARTICLE; AUTOANALYZER; COHORT ANALYSIS; COLORIMETRY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LUNG BIOPSY; LUNG CYST; LUNG FUNCTION; LYMPH NODE; LYMPHANGIOLEIOMYOMATOSIS; MAJOR CLINICAL STUDY; PHENOTYPE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RESPIRATORY TRACT PARAMETERS; SENSITIVITY AND SPECIFICITY; BLOOD; CLINICAL TRIAL; LUNG FUNCTION TEST; MIDDLE AGED; STANDARD;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; LYMPHANGIOLEIOMYOMATOSIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY FUNCTION TESTS; VASCULAR ENDOTHELIAL GROWTH FACTOR D; YOUNG ADULT;

EID: 84859801960     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-34     Document Type: Article

References (30)

1. Johnson S. Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms. Thorax 1999, 54:254-264.
2. Ryu JH, Moss J, Beck GJ, Lee J-C, Brown KK, Chapman JT, Finlay GA, Olson EJ, Ruoss SJ, Maurer JR, et al. The NHLBI Lymphangioleiomyomatosis registry: characteristics of 230 Patients at Enrollment. Am J Respir Crit Care Med 2006, 173:105-111.
3. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000, 97:6085-6090.
4. Johnson SR. Lymphangioleiomyomatosis. Eur Respir J 2006, 27:1056-1065.
5. Bernstein SM, Newell JD, Adamczyk D, Mortenson RL, King TE. Lynch DA: How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis?. Am J Respir Crit Care Med 1995, 152:2138-2143.
6. Matsui K, Tatsuguchi A, Valencia J, Yu Z, Bechtle J, Beasley MB, Avila N, Travis WD, Moss J, Ferrans VJ. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 2000, 31:1242-1248.
7. Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA. Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int 2006, 70:1777-1782.
8. Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y, Iwakami S, Fukuchi Y, Hino O. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 2002, 47:20-28.
9. Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med 2001, 164:1537-1540.
10. Colombat M, Boccon-Gibod L, Carton S. An unusual renal angiomyolipoma with morphological lymphangioleiomyomatosis features and coexpression of oestrogen and progesterone receptors. Virchows Arch 2002, 440:102-104.
11. Mahadeva R, Stewart S, Wallwork J. Metastatic endometrial stromal sarcoma masquerading as pulmonary lymphangioleiomyomatosis. J Clin Pathol 1999, 52:147-148.
12. Colombat M, Stern M, Groussard O, Droz D, Brauner M, Valeyre D, Mal H, Taille C, Monnet I, Fournier M, et al. Pulmonary cystic disorder related to light chain deposition disease. Am J Respir Crit Care Med 2006, 173:777-780.
13. Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, Reynaud-Gaubert M, Boehler A, Brauner M, Popper H, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010, 35:14-26.
14. Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, Doyle T, Elmslie F, Saggar A, de Vries PJ, Sampson JR. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008, 358:200-203.
15. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, et al. Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis. N Engl J Med 2011, 364:1595-1606.
16. Johnson SR, Tattersfield AE. Decline in Lung Function in Lymphangioleiomyomatosis . Relation to Menopause and Progesterone Treatment. Am J Respir Crit Care Med 1999, 160:628-633.
17. Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010, 138:674-681.
18. Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009, 135:1293-1300.
19. Greenlee KJ, Werb Z, Kheradmand F. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev 2007, 87:69-98.
20. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-839.
21. Odajima N, Betsuyaku T, Nasuhara Y, Inoue H, Seyama K, Nishimura M. Matrix metalloproteinases in blood from patients with LAM. Respir Med 2009, 103:124-129.
22. Valencia JC, Pacheco-Rodriguez G, Carmona AK, Xavier J, Bruneval P, Riemenschneider WK, Ikeda Y, Yu ZX, Ferrans VJ, Moss J. Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2006, 35:40-47.
23. Bush A, Cramer D. Guidelines for the measurement of respiratory function. Respir Med 1994, 88:798.
24. McCann CJ, Glover BM, Menown IB, Moore MJ, McEneny J, Owens CG, Smith B, Sharpe PC, Young IS, Adgey JA. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J 2008, 29:2843-2850.
25. Kuenz B, Lutterotti A, Ehling R, Gneiss C, Haemmerle M, Rainer C, Deisenhammer F, Schocke M, Berger T, Reindl M. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One 2008, 3:e2559.
26. Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 2008, 358:199-200.
27. Hayashi T, Fleming MV, Stetler-Stevenson WG, Liotta LA, Moss J, Ferrans VJ, Travis WD. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol 1997, 28:1071-1078.
28. Lee PS, Tsang SW, Moses MA, Trayes-Gibson Z, Hsiao LL, Jensen R, Squillace R, Kwiatkowski DJ. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Am J Respir Cell Mol Biol 2009, 42:227-234.
29. Ramchandran R, Kasturi S, Douglas JG, Sen I. Metalloprotease-mediated cleavage secretion of pulmonary ACE by vascular endothelial and kidney epithelial cells. Am J Physiol 1996, 271:H744-H751.
30. Wang L, Tian XL, Gui YS, Peng M, Cai BQ, Zhu YJ. The St. George's Respiratory Questionnaire in lymphangioleiomyomatosis. Chin Med Sci J 2010, 25:140-145.